🎉 M&A multiples are live!
Check it out!

Rein Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Rein Therapeutics and similar public comparables like Benevolent AI, Galapagos, and Vivoryon Therapeutics.

Rein Therapeutics Overview

About Rein Therapeutics

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.


Founded

2001

HQ

United States of America
Employees

11

Website

reintx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$19.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Rein Therapeutics Financials

Rein Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Rein Therapeutics achieved revenue of n/a and an EBITDA of -$28.0M.

Rein Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Rein Therapeutics valuation multiples based on analyst estimates

Rein Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$15.2M -$28.0M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$27.3M -$15.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Rein Therapeutics Stock Performance

As of April 15, 2025, Rein Therapeutics's stock price is $2.

Rein Therapeutics has current market cap of $36.5M, and EV of $19.2M.

See Rein Therapeutics trading valuation data

Rein Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$19.2M $36.5M XXX XXX XXX XXX $-2.76

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Rein Therapeutics Valuation Multiples

As of April 15, 2025, Rein Therapeutics has market cap of $36.5M and EV of $19.2M.

Rein Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Rein Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Rein Therapeutics and 10K+ public comps

Rein Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $19.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.7x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Rein Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Rein Therapeutics Valuation Multiples

Rein Therapeutics's NTM/LTM revenue growth is n/a

Rein Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.6M for the same period.

Over next 12 months, Rein Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Rein Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Rein Therapeutics and other 10K+ public comps

Rein Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 84% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Rein Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Rein Therapeutics M&A and Investment Activity

Rein Therapeutics acquired  XXX companies to date.

Last acquisition by Rein Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Rein Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Rein Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Rein Therapeutics

When was Rein Therapeutics founded? Rein Therapeutics was founded in 2001.
Where is Rein Therapeutics headquartered? Rein Therapeutics is headquartered in United States of America.
How many employees does Rein Therapeutics have? As of today, Rein Therapeutics has 11 employees.
Who is the CEO of Rein Therapeutics? Rein Therapeutics's CEO is Dr. James Brian Windsor, PhD.
Is Rein Therapeutics publicy listed? Yes, Rein Therapeutics is a public company listed on NAS.
What is the stock symbol of Rein Therapeutics? Rein Therapeutics trades under RNTX ticker.
When did Rein Therapeutics go public? Rein Therapeutics went public in 2017.
Who are competitors of Rein Therapeutics? Similar companies to Rein Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Rein Therapeutics? Rein Therapeutics's current market cap is $36.5M
Is Rein Therapeutics profitable? Yes, Rein Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.